Branding Clinical Development In-Vitro 
pharmaphorum
NOVEMBER 9, 2022
A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. Inhibition of the mPTP has been shown, however, to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models.
The Pharma Data
APRIL 4, 2022
Chief Medical Officer and Head of Global Product Development, Roche. About the Actemra®/RoActemra® (tocilizumab) COVID-19 Clinical Trial Programme Roche’s clinical trial programme evaluated the safety and efficacy of Actemra/RoActemra in hospitalised patients with COVID-19. A decision on U.S. Actemra/RoActemra is not U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 29, 2022
Among the infants with an available assessment (n=48) treated with Evrysdi, 32 infants maintained and four gained the ability to sit without support for at least five seconds since month 24, as assessed by the Gross Motor Scale of the Bayley Scales of Infant and Toddler Development Third Edition (BSID-III).
The Pharma Data
MAY 31, 2022
More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Jude Children’s Research Hospital.
The Pharma Data
MAY 27, 2022
Glofitamab is being investigated in several clinical trials and explored in earlier lines of lymphoma treatment. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.
The Pharma Data
JANUARY 31, 2021
As a first step, Sosei Heptares and Metrion will combine their respective capabilities in a drug discovery program to identify novel, highly specific drug leads for further development against a single ion channel associated with neurological diseases. ” About Sosei Heptares.
The Pharma Data
MAY 15, 2023
Roche’s Chief Medical Officer and Head of Global Product Development. The sBLA is based on results from the phase III BALATON and COMINO studies that demonstrated treatment with Vabysmo provided early and sustained improvement in vision, meeting the primary endpoint of non-inferior visual acuity gains at 24 weeks compared to aflibercept.
Expert insights. Personalized for you.
52 
Let's personalize your content